Radiopharm Theranostics Limited - Sponsored ADR
RADX Healthcare Biotechnology
Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.
Follow RADX
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
2.81 | 22.66 | 18.86 | 23.74 |
+1 more quarter Free account |
Receivables |
11.84 | 7.46 | 6.74 | 4.07 | |
Other current assets |
0.23 | 0.11 | 0.22 | 1.09 | |
Total current assets |
14.88 | 30.22 | 25.81 | 28.90 | |
Property, Plant, Equpment (Net) |
— | 0.03 | — | 0.04 | |
Long-Term Investments |
— | — | — | 0.03 | |
Goodwill and Intangible Assets (Total) |
25.90 | 29.59 | 30.16 | 31.27 | |
Total non-current assets |
25.90 | 29.62 | 30.16 | 31.30 | |
Total Assets |
40.81 | 59.85 | 56.01 | 60.23 | |
Accounts Payable |
7.15 | 7.03 | 6.05 | 4.78 | |
Current Part of Capital Lease |
— | — | 0.00 | — | |
Current Part of Taxes to Pay |
— | — | 0.00 | — | |
Current Revenue (Deferred) |
— | 0.67 | — | 2.06 | |
Other current liabilities |
5.68 | 2.34 | 3.62 | 3.79 | |
Total current liabilities |
12.83 | 10.04 | 9.67 | 8.56 | |
Non-current Revenue (Deferred) |
— | — | 0.00 | — | |
Minority Interests |
— | — | 0.00 | — | |
Non-current Liabilities (Other) |
12.84 | 17.02 | 18.57 | 17.79 | |
Total non-current liabilities |
12.84 | 17.02 | 18.57 | 17.79 | |
Total liabilities |
25.66 | 27.06 | 28.24 | 26.35 | |
Additional Paid In Capital |
— | — | 0.00 | — | |
Preferred Stock (Total) |
— | — | 0.00 | — | |
Common Stock (Net) |
142.48 | 137.80 | 114.34 | 109.64 | |
Retained Earnings |
(135.51) | (113.14) | (94.38) | (83.25) | |
Treasury Stock |
— | — | 0.00 | — | |
Shareholders Equity (Other) |
8.18 | 9.33 | 7.80 | 7.50 | |
Common Equity (Total) |
15.15 | 32.78 | 27.76 | 33.88 | |
Shareholders Equity (Total) |
15.15 | 32.78 | 27.76 | 33.88 | |
Shareholders Equity and Liabilities (Total) |
40.81 | 59.85 | 56.01 | 60.23 | |
Shares (Common) |
— | 11.81 | — | 7.34 | |
Shareholders Equity (Tangible) |
(10.75) | 3.19 | (2.40) | 2.61 | |
Net Debt |
(2.81) | (22.66) | (18.86) | (23.74) |